Coherus BioSciences Future Growth
Future criteria checks 5/6
Coherus BioSciences is forecast to grow earnings and revenue by 47.4% and 14.7% per annum respectively. EPS is expected to grow by 53.3% per annum. Return on equity is forecast to be 57.7% in 3 years.
Key information
47.4%
Earnings growth rate
53.3%
EPS growth rate
Biotechs earnings growth | 31.0% |
Revenue growth rate | 14.7% |
Future return on equity | 57.7% |
Analyst coverage | Good |
Last updated | 28 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 436 | 37 | N/A | N/A | 7 |
12/31/2025 | 354 | -15 | N/A | N/A | 7 |
12/31/2024 | 259 | 60 | N/A | N/A | 6 |
3/31/2024 | 302 | -59 | -154 | -153 | N/A |
12/31/2023 | 257 | -238 | -176 | -175 | N/A |
9/30/2023 | 211 | -217 | -230 | -262 | N/A |
6/30/2023 | 182 | -264 | -213 | -245 | N/A |
3/31/2023 | 183 | -271 | -225 | -256 | N/A |
12/31/2022 | 211 | -292 | -246 | -241 | N/A |
9/30/2022 | 239 | -279 | -231 | -193 | N/A |
6/30/2022 | 276 | -230 | -180 | -143 | N/A |
3/31/2022 | 304 | -210 | -121 | -93 | N/A |
12/31/2021 | 327 | -287 | -39 | -37 | N/A |
9/30/2021 | 364 | -232 | -90 | 48 | N/A |
6/30/2021 | 395 | -165 | -60 | 82 | N/A |
3/31/2021 | 443 | -76 | -16 | 142 | N/A |
12/31/2020 | 476 | 132 | 139 | 154 | N/A |
9/30/2020 | 489 | 162 | 113 | 139 | N/A |
6/30/2020 | 487 | 181 | 125 | 146 | N/A |
3/31/2020 | 435 | 145 | 84 | 99 | N/A |
12/31/2019 | 356 | 90 | 15 | 28 | N/A |
9/30/2019 | 232 | -12 | -38 | -37 | N/A |
6/30/2019 | 121 | -118 | -136 | -134 | N/A |
3/31/2019 | 37 | -185 | -184 | -183 | N/A |
12/31/2018 | N/A | -209 | -160 | -159 | N/A |
9/30/2018 | N/A | -196 | -143 | -142 | N/A |
6/30/2018 | N/A | -196 | -143 | -141 | N/A |
3/31/2018 | 1 | -208 | -164 | -161 | N/A |
12/31/2017 | 2 | -238 | N/A | -200 | N/A |
9/30/2017 | 2 | -265 | N/A | -257 | N/A |
6/30/2017 | 165 | -122 | N/A | -278 | N/A |
3/31/2017 | 178 | -137 | N/A | -250 | N/A |
12/31/2016 | 190 | -127 | N/A | -253 | N/A |
9/30/2016 | 199 | -104 | N/A | -160 | N/A |
6/30/2016 | 44 | -259 | N/A | -158 | N/A |
3/31/2016 | 37 | -248 | N/A | -151 | N/A |
12/31/2015 | 30 | -223 | N/A | -108 | N/A |
9/30/2015 | 26 | -200 | N/A | -147 | N/A |
6/30/2015 | 35 | -137 | N/A | -92 | N/A |
3/31/2015 | 33 | -103 | N/A | -72 | N/A |
12/31/2014 | 31 | -87 | N/A | -24 | N/A |
9/30/2014 | 26 | -73 | N/A | 14 | N/A |
6/30/2014 | 10 | -86 | N/A | 41 | N/A |
3/31/2014 | 6 | -70 | N/A | 37 | N/A |
12/31/2013 | 3 | -54 | N/A | 15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8C5 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: 8C5 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 8C5 is expected to become profitable in the next 3 years.
Revenue vs Market: 8C5's revenue (14.7% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 8C5's revenue (14.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8C5's Return on Equity is forecast to be very high in 3 years time (57.7%).